Harvard Bioscience Inc income statement

In fiscal 2025, Harvard Bioscience Inc reported revenue of $86.5m, down 8.1% on the year before, operating income of −$48.6m (a -56.1% margin) and net income of −$56.7m, or −$1.28 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Harvard Bioscience Inc: income statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	86	108	109	111	105	109	109	105	77	121	116	102	119	113	112	94	87	88
Cost of revenue	44	56	59	59	57	59	60	56	38	58	52	44	51	53	46	39	37	37
Gross profit	42	52	50	52	48	49	49	48	39	63	64	58	68	61	66	55	50	51
Research and development	4	5	4	4	4	5	6	5	6	11	11	9	11	12	12	10	9	9
Selling and marketing	12	16	17	18	17	18	21	20	15	24	23	20	25	25	24	22	19	20
General and administrative	15	18	18	18	18	17	20	21	18	21	23	24	24	24	23	21	18	18
Operating income	8	10	8	8	2	7	−2	−3	−1	1	0	0	2	−7	2	−6	−49	−0
Interest expense	0	1	1	1	1	1	1	1	1	5	—	—	—	—	—	1	1	—
Income before tax	10	10	7	7	0	4	−4	−3	−3	−8	−6	−7	−0	−9	−3	−12	−57	−11
Income tax	3	−9	2	2	−0	2	15	1	−1	−4	−1	1	0	0	1	1	−1	−0
Net income	7	19	4	2	−2	2	−19	−4	−1	−3	−5	−8	−0	−10	−3	−12	−57	−10
Diluted EPS	$0.24	$0.65	$0.13	$0.08	−$0.06	$0.07	−$0.57	−$0.13	−$0.02	−$0.08	−$0.12	−$0.20	−$0.01	−$0.23	−$0.08	−$0.28	−$1.28	—
Diluted shares (average)	30m	29m	30m	30m	32m	33m	34m	34m	35m	36m	38m	39m	40m	41m	42m	44m	44m	—
EBITDA	9	14	13	12	3	8	0	−1	1	3	2	2	4	−5	3	−4	−47	2

US$ millions unless shown otherwise. Fiscal quarters.

Harvard Bioscience Inc: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	22	25	22	20	21	24	21	23
Cost of revenue	9	11	10	9	9	10	9	10
Gross profit	13	14	12	12	12	14	12	13
Research and development	3	2	2	2	2	2	2	2
Selling and marketing	6	5	5	5	5	5	5	5
General and administrative	5	5	5	4	4	4	5	5
Operating income	−2	0	−50	−1	0	2	−1	−1
Interest expense	—	—	—	1	—	—	—	1
Income before tax	−4	1	−51	−2	−1	−3	−3	−3
Income tax	0	1	−0	0	0	−0	0	0
Net income	−5	0	−50	−2	−1	−3	−3	−3
Diluted EPS	−$0.11	$0.01	−$11.42	−$0.52	−$0.30	−$0.06	−$0.77	−$0.64
EBITDA	−1	0	−49	−0	1	2	−1	−1

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CDXS vs HBIO BNR vs HBIO BDSX vs HBIO HBIO vs MDXH

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Harvard Bioscience Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Harvard Bioscience Inc.